FeesSafety
Pluang+

New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

Market News
12 Oct 2026, 00:00 WIB
Na
View Source
Bullish
New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs rose to 41.9%, the highest reported for any non-invasive blood test in a pivotal study. Overall colorectal cancer detection remained strong at 80.4% sensitivity with 90% specificity. These improvements could make colorectal cancer screening more accessible and effective for unscreened populations, with detailed results to be presented at ACG 2026.

Freenome's new colorectal cancer screening test shows improved sensitivity for advanced precancerous lesions, reaching 18.2% compared to 13.7% previously. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 11, 2026 23:11 WIB: out of 128 priced US health-sector stocks, 109 rose and 18 fell. Notable movers include Moderna (MRNA) up 14.21% at USD 225.00 with a typical hold time of 59 days, Heron Therapeutics (HRTX) up 13.37% at USD 0.41, and Humana (HUM) up 11.34% at USD 431.03.

More News

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

Coupang leads South Korea's e-commerce with strong logistics but faces losses and regulatory challenges, including a major data breach. DICK'S Sporting Goods, expanding through Foot Locker acquisition, shows strong profitability, a solid dividend, an...

Market News
Neutral
19 minutes ago
AMD stock soars 140% in 2026, Nvidia lags but both poised for strong earnings growth by 2028.

AMD stock soars 140% in 2026, Nvidia lags but both poised for strong earnings growth by 2028.

In 2026, AMD's stock surged 140% due to strong growth in AI chips and server CPUs, with revenue and earnings expected to continue rising sharply through 2028. Nvidia, despite a 20% stock drop and leadership uncertainty, reported impressive revenue an...

Market News
Neutral
28 minutes ago
Berkshire Hathaway valued at $700 per share, driven by cash, stocks, and growing businesses under CEO Greg Abel.

Berkshire Hathaway valued at $700 per share, driven by cash, stocks, and growing businesses under CEO Greg Abel.

Berkshire Hathaway holds $352 billion in cash and Treasury bills and a $336 billion stock portfolio, covering over half its current share price. CEO Greg Abel's patient management and steady growth in operating businesses, including railroad and util...

Market News
Bullish
49 minutes ago
Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Gilead Sciences increased its dividend by 3.8% for the 11th consecutive year, supported by strong free cash flow of $10.6 billion over nine months and a conservative payout ratio below 30%. The company maintains a dominant position in HIV therapies w...

Company Fundamentals
Bullish
1 hour ago
Nvidia stock plunges 23% amid CEO resignation and investigations, trading at a record low P/E of 8.

Nvidia stock plunges 23% amid CEO resignation and investigations, trading at a record low P/E of 8.

Nvidia experienced its worst week since 2008, dropping 23% following CEO Jensen Huang's resignation and multiple investigations into chip exports to China. Despite a strong earnings report showing 103% revenue growth and raised guidance, the stock tr...

Market News
Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App